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ochester, Minnesota; and Bethesda, Maryland
Review of the trend in cardiovascular disease mortality for males and females clearly
demonstrated that whereas the trend shows a decline in males this decline is not observed in
females. Multiple important reports emerged from the initial phases of the Women’s
Ischemic Syndrome Evaluation (WISE) study that may have significant clinical implications
for our approach to cardiovascular disease in women. The data derived from the WISE study
certainly provided important information to our understanding of the approach to women
with cardiovascular disease. The clinical presentation may be different, and a gender-oriented
questionnaire may enhance our diagnosis. In a multivariable model, low hemoglobin was
associated with significantly higher risk of adverse outcomes. The risk factor assessment and
the risk factor profiles in women that are associated with coronary artery disease may be
different. Based on the studies from the WISE study, metabolic syndrome is a leading and a
major risk factor in women. Moreover, the data further support the concept that the
mechanism of ischemia in women may be localized in the microvascular coronary arteries.
Therefore, the diagnoses of coronary microvascular dysfunction or endothelial dysfunction
should be considered in women with chest pain who do not have obstructive coronary artery
disease. It may be advantageous to add such diagnostic tests when the conventional tests are
nondiagnostic. A revised clinical approach to cardiovascular disease in women may be
designed and tested based on these findings. (J Am Coll Cardiol 2006;47:59S–62S) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.083by the American College of Cardiology Foundation
e
n
r
e
A
s
t
w
a
(
r
w
t
t
d
h
a
S
l
s
n
m
i
poronary heart disease (CHD) is the leading cause of
ortality and morbidity in the U.S. More women than men
ave died annually from ischemic heart disease (IHD) since
984, and coronary artery disease (CAD) is the cause of over
50,000 deaths in women each year. The evaluation of IHD
n women presents a unique and sometimes difficult chal-
enge for clinicians, owing to the greater symptom burden,
reater functional disability, and lower prevalence of ob-
tructive coronary disease as compared to men. Objective
vidence of ischemia, whether symptomatic or asymptom-
tic, identifies individuals with an adverse prognosis. The
esults of older trials largely defined the relative places of
edical therapy and coronary surgery for the era in which
hey were conducted. A number of significant changes in
election of patients for surgery, in surgical methods, and in
edical therapies have occurred. New pharmacologic and
evascularization strategies are now available to relieve
schemia. However, the diagnosis and treatment of CHD
ave been primarily based on research conducted in men,
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his work was supported by National Institutes of Health grant numbers HL-63911
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004, accepted October 25, 2004.ither excluding women entirely or including only limited
umbers of women and minorities.
Beginning in the early 1970s, with the popularization of
evascularization, a number of studies reported on the
xperience of coronary artery bypass surgery. The Coronary
rtery Surgery Study (CASS) was a landmark multicenter
tudy conducted in the 1970s that influenced clinical prac-
ice in CAD for many years to come. In that seminal study,
hich prospectively enrolled patients referred for coronary
ngiography, only 24% of the more than 24,959 patients
registry and randomized trial) enrolled were women. This
epresented one of the largest, if not the largest, cohort of
omen who had angiography to document CAD at that
ime. Despite the relatively small proportion of women in
he CASS trial, important conclusions regarding gender
ifferences in coronary artery disease were evident. First, a
igh proportion of women with the clinical diagnosis of
ngina “failed” to show evidence of CAD at angiography.
econd, the use of the traditional risk factor assessment was
imited in prediction of CAD in individual patients and
pecifically in women (1,2). The study also generated a
umber of interesting findings. Women were 4.5 times
ore likely to have false-positive exercise test response even
n the presence of normal coronary angiography. However,
ositive exercise testing was potentially more helpful in
redicting the diagnosis of CAD in women than in men (2).
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Ischemic Heart Disease in Women February 7, 2006:59S–62Subsequent reports describing these CASS trial results implied
hat these paradoxical findings might be explained by the
elatively lower incidence of CAD among women compared to
en; however, critical inquiry was not undertaken.
It has been only recently realized that it may not be
ppropriate to extrapolate clinical decisions regarding
omen from studies performed in exclusively or predomi-
antly male cohorts. This realization is underscored by the
larming epidemiologic data demonstrating that IHD is the
eading cause of morbidity and mortality for women, and
hat the gap between women and men in terms of incidence
nd mortality narrows with advancing age. Review of the
rends in cardiovascular disease mortality for males and
emales clearly demonstrates declines in males, which is not
bserved in females. These data suggest that our concept
nd understanding of CAD in women are clearly far from
omplete.
In response to a need for sex-specific IHD research, the
ational Heart, Lung, and Blood Institute (NHLBI)-
unded a number of clinical studies. In 1996, NHLBI
unded the Women’s Ischemia Syndrome Evaluation
WISE) to improve the reliability of diagnostic testing for
HD in women, and to develop safe, efficient, and cost-
ffective new diagnostic approaches for women with sus-
ected IHD. A number of important reports continue to
merge from the study that may have significant clinical
mplications for our approach to cardiovascular disease in
omen. Moreover, a revised clinical approach to IHD in
omen may be designed and tested based on these findings.
linical evaluation. One of the fundamental steps in the
ccurate diagnosis of CAD is a thorough history and
hysical examination. The typical textbook symptoms of
ubsternal chest pain or pressure radiating to the arms may
ot be the primary symptoms in women presenting with
AD. Other symptoms such as dyspnea, fatigue, and lack of
nergy may be predominant (3). The new onset of the
ymptoms and their relationship to activity has more clinical
elevance than their physical location (4,5). Women report
ymptoms more often during daily activities and mental
tress than during exercise (6). Special attention should be
iven to the woman’s social history, particularly to the
resence of stressful environment or situations. Recent
eports suggest that the incidence of transient global myo-
ardial ischemia in response to mental stress may be higher
Abbreviations and Acronyms
BMI  body mass index
CAD  coronary artery disease
CASS  Coronary Artery Surgery Study
CHD  coronary heart disease
Hgb  hemoglobin
IHD  ischemic heart disease
NHLBI  National Heart, Lung, and Blood Institute
WISE  Women’s Ischemia Syndrome Evaluationn women than in men (7). Because, among premenopausal momen undergoing coronary angiography for suspected
yocardial ischemia, disruption of ovulatory cycling char-
cterized by hypoestrogenemia of hypothalamic origin ap-
ears to be associated with angiographic CAD (8), a
etailed history should include this information for the
lobal assessment. Thus, a female-specific questionnaire
ased on the data from the WISE study may enhance our
iagnosis.
One of the laboratory tests that is often overlooked as a
otential risk factor is hemoglobin (Hgb). Low hemoglobin
evels are associated with higher risk for adverse cardiovas-
ular outcomes in women evaluated for suspected ischemia
n the absence of acute myocardial infarction or congestive
eart failure. However, the prognostic significance of Hgb
n women with suspected ischemia is unclear. Recent
vidence from the WISE study demonstrated that women
ith low Hgb (12 g/dl) have a higher risk of death from
ny cause and total adverse outcomes (9). In a multivariable
odel, low Hgb was associated with significantly higher risk
f adverse outcomes. Also, anemic women had shorter
urvival time free of adverse outcome. These findings may
ot only be relevant for understanding the mechanism of
AD in women, but also have potential therapeutic
mplications.
Although women are generally at lower risk than men,
he combination (i.e., clustering of novel risk markers) acts
dditively and/or multiplicatively to increase risk and there-
ore risk assessment in female cohorts. The metabolic
yndrome is a leading and a major risk factor in women. In
he WISE study , the presence of the metabolic syndrome
as independently associated with increased risk of death
nd major cardiovascular events as opposed to increased
ody mass index (BMI) (10). Because the metabolic syn-
rome but not BMI predicts future cardiovascular risk in
omen, it may be more important to assess the whole
pectrum of the metabolic syndrome rather than the BMI
lone and to recommend control of all modifiable risk
actors in both normal and overweight persons to prevent
ransition to the metabolic syndrome (11). For example,
mong women with the metabolic syndrome and high levels
f high sensitivity C- reactive protein, the risk of cardiovas-
ular events was similar to that of diabetic women.
oninvasive functional testing. The lack of correlation
etween the symptoms in women and conventional func-
ional testing may again indicate that these tests were
eveloped in studies that were predominately male, and may
e less applicable for the diagnosis of CAD in women.
lthough women have less extensive obstructive disease
han do men, but a similar or worse prognosis (12), this
enders important the need to diagnose such CAD in
omen but poses a challenge for further development of
oninvasive diagnostic methods. It may be speculated that
unctional tests based on differential perfusion between
ascular territories may be less beneficial for the diagnosis of
yocardial ischemia in women, compared with global
easures of ischemia or risk.
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February 7, 2006:59S–62S Ischemic Heart Disease in WomenAmong the WISE study women with suspected myocar-
ial ischemia in the absence of obstructive CAD, the
bnormal phosphorus-31 nuclear magnetic resonance car-
iac stress test was a significant predictor of poor cardio-
ascular outcomes in women with chest pain, independent
f the presence of CAD and CAD risk factors. The test was
ble to identify women who were more likely to have
ersistent and worsening angina requiring catheterization
nd hospitalization resulting in greater functional limita-
ions and higher health care costs. These results suggest that
agnetic resonance can have wide utility in evaluating
omen with chest pain, reducing the number of women
ndergoing repeated coronary angiography, and facilitating
reatment before the ischemia worsens (13). The data
urther support the concept that the mechanism of the
yocardial ischemia in women may be localized in the
icrovascular coronary arteries.
oronary angiography. The conventional sequence of
oninvasive functional tests followed by diagnostic coronary
ngiography was derived from large multicenter studies that
ere based on the hypothesis that the cause of the myocar-
ial ischemia is secondary to epicardial obstructive CAD.
owever, it has become apparent that women who present
ith angina have less severe and frequent obstructive CAD
n coronary angiography (12). These observations led to the
otion that women had increased false-positive results in
unction tests. The WISE study results have advanced our
nderstanding of the nature of myocardial ischemia in
omen. Functional rather than structural abnormalities of
he coronary circulation may be the hallmark of the disease
n women. Reis et al. (14) demonstrated that coronary
icrovascular dysfunction can be identified in approxi-
ately half of women with chest pain in the absence of
bstructive CAD and cannot be predicted by risk factors for
therosclerosis or by hormone levels. Moreover, coronary
ow reserve is lower in women than in men, suggesting
otential primary abnormalities in the coronary microcircu-
ation as a source of ischemia in women (15). Furthermore,
n women in the WISE study, coronary endothelial dys-
unction was independently associated with adverse cardio-
ascular outcomes regardless of CAD severity (16). Thus,
he diagnoses of coronary microvascular dysfunction or
ndothelial dysfunction should be considered in women
ith chest pain who do not have obstructive CAD.
ummary and clinical implications. The WISE study
rovides new information to our understanding of the
linical presentation, diagnosis, and prognosis of IHD in
omen. With the use of careful traditional risk factor data
ollection, state-of-the-art technology, and comprehensive
nalyses, the study has a wealth of data applicable to the
iagnosis and management of women with suspected IHD.
A seminal finding from the WISE study relevant to the
ractice of cardiology is that among women referred for
valuation of suspected myocardial ischemia, approximately
0% do not have obstructive coronary disease, and the
rognosis for these women is intermediate in terms of futuredverse cardiac events and persistent symptoms. Practitio-
ers should no longer ignore nonobstructive coronary an-
iograms in women nor call evidence of clear ischemia in
his setting, such as a positive troponin or an abnormal stress
erfusion test, a false positive.
The WISE study has further demonstrated that micro-
ascular ischemia is frequently associated with the signs and
ymptoms of ischemia for this large cohort of women with
onobstructive coronary arteries. Because this abnormal
ascular function is often concomitant with abnormal en-
othelial function, prudent treatment of these women
hould involve aggressive medical therapy directed at im-
roving endothelial function, atherosclerosis, and estab-
ished risk factors, including statin lipid-lowering,
ngiotensin-converting enzyme inhibitors, and aspirin. Fu-
ure WISE and non-WISE clinical trials will be directed at
esting these strategies for reduction of adverse events in
hese women.
The predictive value of novel risk markers demonstrated
n the WISE study may provide us with additional insight
nto the sex-specific differences in the pathophysiology of
HD. For example, because women in general have lower
emoglobin levels compared to men, due to decades of
enstrual cycling and pregnancy-associated losses, it may
lso be prudent to initiate treatment for low hemoglobin
evels in the presence of IHD sooner than current practices
mong women. Clearly, prospective randomized trials will
eed to address the utility, risks, and benefits of this
pproach.
The results of the older trials largely defined the relative
laces of medical therapy and revascularization based pri-
arily on experience from studies consisting largely of men.
n the current pace of the rapid evolution and expansion of
nvasive and noninvasive interventions, there is a need to
ddress the optimal therapy suitable for women. Recent
tudies suggest that gender-specific approaches could be
eneficial in preventing future events. Based on results from
hese studies, it is logical to pose the hypothesis that sex
mproves long-term prognosis. However, many uncertain-
ies remain. Clearly, new studies are needed to prospectively
est and validate the WISE study results in a new popula-
ion and to establish the long-term morbidity and mortality
enefits, and quality of life and health care economics, of
ractice-based sex-targeted strategies. There is no doubt
hat the investment in the WISE study was a “WISE”
ove.
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